Diabetes mellitus (DM) is a chronic metabolic disease with a high prevalence worldwide. Glycated proteins can be used as an indicator of glycemic control, as diabetic patients have increased glycation between different proteins compared to non-diabetic patients. Glycated albumin (GA) accurately reflects short-term and postprandial plasma glucose changes.
Global glycated albumin assay market is estimated to be valued at US$ 571.0 million in 2023 and is expected to exhibit a CAGR of 8.07% during the forecast period (2023-2030).
Analysts’ Views on Global Glycated Albumin Assay Market:
Rising demand for more accurate diagnostics methods for diagnosis of diabetes is expected to drive the market growth over the forecast period. For instance, in March 2022, an article published in Springer Nature, which is a scientific journal, stated the recent developments in biomarkers for diagnosis and screening of type 2 diabetes mellitus.
Figure 1.Global Glycated Albumin Assay Market Share (%), by Product Type, 2023
Global Glycated Albumin Assay Market- Driver
Increasing research and development activity by key players in the market
The glycated albumin assay is used in research and development for the diagnosis of diabetes. Thus, increasing related to glycated albumin assay, by key players in the market is expected to drive the market growth over the forecast period. For instance, in June 2022, Frontiers Media, which is an open source scientific journal, published an article stating the use of glycated albumin to define partial remission in type 1 diabetes.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 571.0 Mn |
| Historical Data for: | 2017 to 2021 | Forecast Period: | 2023 to 2030 |
| Forecast Period 2023 to 2030 CAGR: | 8.07% | 2030 Value Projection: | US$ 983.0 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Asahi Kasei Pharma Corporation, Weldon Biotech Inc., Abbexa Ltd., Laboratory Corporation of America, Biocompare, EFK Diagnostics, Elabscience Biotechnology Inc., Abbot, Diazyme Laboratories Inc., Abnova Corporation, BSBE, Maccura Biotechnology Co.,Ltd., LifeSpan BioSciences Inc., Biomatik, Geno Technology Inc., AMS Biotechnology (Europe) Limited, Epinex Diagnostics Inc., DxGen Corp. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Increasing prevalence of diabetes
The glycated albumin assay technology is used for the diagnosis of diabetes, and thus, the increasing prevalence of diabetes is expected to drive the market growth over the forecast period. For instance, in October 2021, a report published on National Center for Biotechnology Information (NCBI), stated that the prevalence of diabetes in India has risen from 7.1% in 2009 to 8.9% in 2019.
Figure 2. Global Glycated Albumin Assay Market Share (%), by Region, 2023
Global Glycated Albumin Assay Market- Regional Analysis
Among region, North America is expected to dominate the market over the forecast period. This is attributed to increasing adoption of inorganic growth strategies, such as company acquisitions by key players in the region to expand their product portfolio. This is expected to drive the market growth over the forecast period. For instance, in July , LifeSpan BioSciences, a leading provider of antibodies and life science research reagents announced its of Everest Biotech, certified experts in antigen affinity purified goat polyclonal antibodies which will help LifeSpan BioSciences to develop new technologies for glycated albumin assay.
European region is expected to hold the second largest market share over the forecast period, owing to increasing prevalence of chronic kidney diseases in this region, which can use glycated albumin for the diagnosis of kidney diseases, which is expected to drive the market growth over the forecast period. For instance, in February 2022, European parliament stated that in Europe, 100 million people suffer from chronic kidney diseases, and predictions suggest that it will become the fifth leading cause of death globally by 2040.
Global Glycated Albumin Assay Market– Impact of Coronavirus (COVID-19) Pandemic
Coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). According to the World Health Organization (WHO)
However, the COVID-19 pandemic had a positive impact on the global glycated albumin assay market due to increasing prevalence of diabetes and chronic kidney disorders after COVID-19. For instance, in October 2022, according to an article published on Centers for Disease Control and Prevention (CDC), globally .
Global Glycated Albumin Assay Market Segmentation:
The global glycated albumin assay market report is segmented into product type, application, end user and region
Based on Product Type, the market is segmented into human glycated albumin assay and animal glycated albumin assay. Out of which, human glycated albumin assay segment is expected to dominate the glycated albumin assay market during the forecast period, and this is attributed to the increase in product launches by key players in the market.
Based on Application, the glycated albumin assay market is segmented into diagnostics (prediabetes, type 1 diabetes, and type 2 diabetes) and research. Diagnostics segment is expected to dominate the market over the forecast period and this is attributed to the increased prevalence of diabetes around the globe.
Based on End User, the glycated albumin assay market is segmented into hospital, diagnostic centers, research centers, and others. Of which, diagnostic centers segment is expected to dominate the market over the forecast period and this is attributed to the increase in the use of glycated albumin assay for diagnosis of diabetes.
Based on Region, the glycated albumin assay market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. Of which, North America segment is expected to dominate the market over the forecast period and this is attributed to the increasing inorganic growth strategies such as collaboration by key players in the region.
Among all segmentation, application segment has the highest potential due to increased research and development activities with respect to diabetes, anemia, chronic kidney disorders, etc. For instance, in September , an article published in Journal of Laboratory and Precision Medicine (JLPM), which is an open access journal, stated that glycated albumin has been proposed as a biomarker of glycemic control in patients with diabetic nephropathy, anemia, pregnancy, and others.
Global Glycated Albumin Assay Market Cross Sectional Analysis:
In application segment, diagnostics segment held a dominant position in North America region due to an increasing prevalence of anemia and diabetes in the region. For instance, in September 2022, according to the statistics published by Centers for Disease Control and Prevention, 5,633 deaths were reported due to anemia in the U.S.
In end user segment, diagnostic centers segment is dominant in Asia Pacific region, due to an increasing prevalence of diabetes in this region. For instance, in July 2022, an article published by Statista, which is a leading provider of market and consumer data, stated that China has the highest number of diabetic patients with around 141 million people suffering from the diabetes. By the year 2045, it is predicted that China will have around 174 million people with diabetes.
Global Glycated Albumin Assay Market:
On February 2, 2023, Biocompare, a life science product directory, announced its with Scilan, a leading provider of artificial intelligence and machine learning based solutions for life science tool providers which will help Biocompare in developing new artificial intelligence based glycated albumin assays.
On 24 January 2023, Diazyme Laboratories, Inc., a certified medical device manufacturer, announced that it has entered into a partnership with Carolina Liquid Chemistries Corp, a leading provider of chemistry instruments and reagents.
In June 2019, Abbott India Ltd., which is one of the leading multinational pharmaceutical companies, launches first-ever rapid point-of-care hba1c test to aid in the diagnosis of diabetes.
On January 17 July, , EKF Diagnostics Holdings plc, which is a global medical diagnostics business, launched Lucica Glycated Albumin-LA specific test for glycated albumin.
Increasing acquisitions and product launches by key players in the market is expected to create new opportunities and over the forecast period.
Global Glycated Albumin Assay Market: Restraint
Launch of glycated hemoglobin assay for diagnosing diabetes mellitus
The major factor that can hamper the growth of the global glycated albumin assay market over the forecast period is the launch of glycated hemoglobin assay for the diagnosis of diabetes. For instance, in June 2021, Afinion HbA1c Dx assay was developed by got approved by the U.S. Food and Drug Administration for point-of-care test.
Global Glycated Albumin Assay Market: Key Players
Major players operating in the global glycated albumin assay market include Asahi Kasei Pharma Corporation, Weldon Biotech, Inc., Abbexa Ltd., Laboratory Corporation of America, Biocompare, EFK Diagnostics, Elabscience Biotechnology Inc., Abbot, Diazyme Laboratories, Inc., Abnova Corporation, BSBE, Maccura Biotechnology Co.,Ltd., LifeSpan BioSciences Inc., Biomatik, Geno Technology Inc., AMS Biotechnology (Europe) Limited, Epinex Diagnostics Inc., DxGen Corp.
Definition: The glycated albumin (GA) is a test that reflects short-term glycemia and is not influenced by situations that falsely alter A1C levels. Glycated albumin is the higher glycated portion of fructosamine. It is measured by a standardized enzymatic methodology, easy and fast to perform.
Diabetes mellitus is a chronic metabolic disease with a high incidence worldwide. Glycated hemoglobin (A1C) is the reference test for long-term glucose monitoring and has been shown to be associated with chronic complications of diabetes. However, A1C is not recommended in clinical situations that may affect hemoglobin metabolism.
The glycated albumin (GA) is a test that reflects short-term glycemia and is not influenced by situations that falsely alter A1C levels. Glycated albumin is the higher glycated portion of fructosamine. It is measured by a standardized enzymatic methodology, easy and fast to perform.
Market Dynamics
Increasing adoption of inorganic growth strategies, such as company acquisition by key players in the market to expand their product portfolio is expected to drive the market growth over the forecast period. For instance, in September 2021, EKF, a global medical manufacturer of Point-of-Care and Central Laboratory devices, completed the acquisition of Advanced Diagnostic Laboratory LLC, which is a well-known PCR-focused testing laboratory among the pharmaceutical, biotechnology and medical device communities.
The increasing adoption of organic growth strategies such as product launches by key players in the market to expand product portfolio is expected to drive the market growth over the forecast period. For instance, on 3 January 2023, LifeSpan BioSciences Inc, which is a leading provider of antibodies and reagents launched ELISA Kit-LS-F15522, which is a 96-well enzyme-linked immunosorbent assay (ELISA) for the Quantitative detection of human glycated albumin in samples of plasma and serum.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients